Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. TOLAK
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

TOLAK

Medicine - Posted on Nov 03 2020
Active substance (DCI)
  • 5-fluorouracile
history (1)
  • 10/21/20

    TOLAK

    Key points Favourable opinion for reimbursement in the topical treatment of non-hyperkeratotic, non-hypertrophic actinic ker...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01BC02
Manufacturer
PIERRE FABRE
Presentation

TOLAK 40 mg/g, crème
Tube de 20 g (CIP : 34009 301 932 6 6)

All our publications
    Drug therapy Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
G1fxQCtjvwFE3DWF